<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012777</url>
  </required_header>
  <id_info>
    <org_study_id>20100334</org_study_id>
    <nct_id>NCT02012777</nct_id>
  </id_info>
  <brief_title>Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease</brief_title>
  <official_title>Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to
      upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose of
      this pilot study is to administer one dose of propanolol to children with sickle cell disease
      and to measure pre and post dose red cell adhesion. The hypothesis is that a single dose of
      propanolol will decrease red cell adhesion to laminin and endothelial cells as compared to
      baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A similar pilot study has already been conducted in adults and is now being tried in children
      to gather preliminary data for a grant submission. No safety issues were found in the adult
      pilot study. This study will evaluate the effect of different doses of propanolol. The risks
      of this study involve the risks of three (3) blood draws and the risks of propanolol. In
      order to minimize the risks children with sickle cell disease and asthma will be excluded
      because asthma is a contraindication to the use of propanolol. In addition, patients will not
      be hypertensive or bradycardic.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit patients into the study.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 3, 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of the sickle red cell response to epinephrine</measure>
    <time_frame>1-4 weeks</time_frame>
    <description>At study initiation 5mL of blood is drawn to evaluate for red cell adhesion (screening visit or visit 1). At the intervention visit 1-4 weeks later another 5mL of blood will be drawn and patient will have an ECG performed, followed by one dose of propanolol at the stratum that s/he is in. Vitals signs will be monitored (including blood pressure) for 4 hours after drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data regarding the use of propanolol in children with sickle cell disease</measure>
    <time_frame>within 24 hours after drug administration</time_frame>
    <description>New onset wheezing
Onset of low blood pressure defined as blood pressure less than 90/50
Onset of heart rate less than 60 beats/min</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>cohort 1 10mg propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.
Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2 20mg propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3 40mg propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.</description>
    <arm_group_label>cohort 1 10mg propranolol</arm_group_label>
    <arm_group_label>cohort 2 20mg propranolol</arm_group_label>
    <arm_group_label>cohort 3 40mg propranolol</arm_group_label>
    <other_name>propanolol systemic</other_name>
    <other_name>Inderal</other_name>
    <other_name>Inderal LA</other_name>
    <other_name>InnoPran XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of HbSS or HbSBeta0Thal

          2. age 10-17 years

          3. Weight 30kg or greater

          4. Hb 7mg/dL or greater

          5. informed consent

        Exclusion Criteria:

          1. History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion
             during the past 3 months.

          2. pregnancy

          3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension,
             thyroid disease, diabetes, renal insufficiency

          4. concurrent medications: any antihypertensive medication, diuretics, thyroid
             replacement medications, any arrythmia medication, insulin, hypoglycaemic medication

          5. history of allergy to sulfonamides

          6. elevated BUN or creatinine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofelia A Alvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010 Aug;163(2):269-74. doi: 10.1111/j.1365-2133.2010.09848.x. Epub 2010 May 8. Review.</citation>
    <PMID>20456345</PMID>
  </reference>
  <results_reference>
    <citation>Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649-51. doi: 10.1056/NEJMc0708819.</citation>
    <PMID>18550886</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009 Sep-Oct;26(5):610-4. doi: 10.1111/j.1525-1470.2009.00975.x.</citation>
    <PMID>19840322</PMID>
  </results_reference>
  <results_reference>
    <citation>Zimmermann AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol. 2010 Apr;74(4):338-42. doi: 10.1016/j.ijporl.2010.01.001. Epub 2010 Feb 1. Review.</citation>
    <PMID>20117846</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010 Nov-Dec;53(5-6):200-8. doi: 10.1016/j.vph.2010.08.002. Epub 2010 Aug 20.</citation>
    <PMID>20732454</PMID>
  </results_reference>
  <results_reference>
    <citation>Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011 Apr;64(4):445-51. doi: 10.1016/j.bjps.2010.07.009. Epub 2010 Aug 24.</citation>
    <PMID>20797926</PMID>
  </results_reference>
  <results_reference>
    <citation>Schiestl C, Neuhaus K, Zoller S, Subotic U, Forster-Kuebler I, Michels R, Balmer C, Weibel L. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011 Apr;170(4):493-501. doi: 10.1007/s00431-010-1324-2. Epub 2010 Oct 9.</citation>
    <PMID>20936416</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang, MW. Journal Watch Dermatology. Nov 6, 2009 Propanolol for Infantile Hemangioma: Safety Issues and Proposed Protocol</citation>
  </results_reference>
  <results_reference>
    <citation>Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010 Jul;146(7):775-8. doi: 10.1001/archdermatol.2010.158.</citation>
    <PMID>20644039</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Ofelia Alvarez</investigator_full_name>
    <investigator_title>Professor of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>propanolol</keyword>
  <keyword>red blood cell adhesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

